Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Despite challenges like high costs and regulatory complexities, Europe's vibrant research ecosystem and EMA's supportive ATMP ...
Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from ...
4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...
A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.
Pharmaceutical Technology on MSN
Eli Lilly buys Adverum in eye disease gene therapy punt
Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback